RARE Act

Bill Number

S. 3716

Origin Chamber

Senate

Congress

119th Congress, Session 2

Status

Introduced

Latest Action

2026-01-28: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Last Updated

2026-02-19T03:53:21Z

AI-Generated Summary

Purpose

The Retaining Access and Restoring Exclusivity Act (RARE Act) aims to narrow the scope of market exclusivity for drugs approved to treat rare diseases or conditions (known as orphan drugs). By limiting exclusivity to specific approved uses rather than the entire rare condition, the bill seeks to promote competition, potentially improving access to affordable treatments while preserving incentives for developing drugs for rare diseases.

Key Provisions

• Amendment to Exclusivity Rules: Modifies Section 527 of the Federal Food, Drug, and Cosmetic Act to restrict the 7-year period of exclusive approval or licensure (which prevents other drugs from being approved for the same purpose) to the "same approved use or indication" within a rare disease or condition, rather than the broader rare disease itself.
• Definitions and Clarifications:
• Replaces references to the "same disease or condition" with "same approved use or indication."
• Specifies that exclusivity applies only to the particular approved use for which the original drug was granted protection.
• Defines "approved use or indication" as the specific treatment purpose approved by the FDA under drug approval laws or licensed under public health service laws for orphan-designated drugs.
• Retroactive Application: The changes apply to all orphan drugs, regardless of when they were designated as orphans or approved/licensed.

Significant Changes to Existing Law

• Narrowing of Exclusivity Scope: Under current law, orphan drugs receive 7 years of exclusivity for the entire rare disease or condition, blocking competing drugs even for different uses within that condition. The bill limits this to only the exact approved use or indication, allowing other drugs to enter the market sooner for alternative treatments of the same rare condition.
• Broad Applicability: Unlike some amendments that apply only prospectively, this bill retroactively affects existing orphan drugs, potentially ending or limiting exclusivity periods that are already in place.

Potential Impacts

• On Government Agencies: The Food and Drug Administration (FDA) will need to revise its approval processes and interpretations to enforce the narrower exclusivity, which may increase administrative workload for reviewing competing applications but could streamline approvals for non-overlapping uses.
• On Citizens: Patients with rare diseases may gain faster access to alternative treatments or generic versions, potentially lowering drug costs and improving options, though it could affect the development of new orphan drugs if incentives are reduced.
• On International Relations: Minimal direct impact, as the bill focuses on U.S. drug approval laws; however, it may influence global pharmaceutical markets by altering U.S. exclusivity patterns, potentially benefiting international generic manufacturers.

Main Stakeholders Affected

• Pharmaceutical Companies: Developers of orphan drugs may face reduced market protection, limiting revenue potential but encouraging focus on specific innovations; generic drug makers could benefit from easier market entry.
• Patients and Advocacy Groups: Individuals with rare diseases and organizations like patient advocacy networks stand to gain from increased competition and access to treatments.
• Healthcare Providers and Insurers: Doctors and insurance companies may see more affordable options, reducing treatment costs for rare conditions.
• FDA and Regulators: Directly responsible for implementing changes, affecting how they designate and approve orphan drugs.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: The retroactive application could lead to legal challenges from drug manufacturers claiming violations of vested property rights in existing approvals, potentially resulting in litigation over contract-like exclusivity periods granted under prior law.
• Constitutional Implications: No direct challenges anticipated, but retroactivity might raise due process concerns if seen as impairing established economic expectations without sufficient public interest justification.
• Political Implications: The bill balances drug innovation incentives with access and affordability goals, likely sparking debate in Congress and among stakeholders on rare disease policy; it reflects broader efforts to address high drug prices without fully repealing orphan drug benefits established in 1983.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Baldwin, Tammy [D-WI]

Recent Actions

• 2026-01-28: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2026-01-28: Introduced in Senate

Bill Versions

• Retaining Access and Restoring Exclusivity Act — issued 2026-01-28 — PDF (3 pages)